4.8 Article

von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage

Journal

ONCOGENE
Volume 30, Issue 28, Pages 3127-3138

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.40

Keywords

von Hippel-Lindau; Skp2; DNA damage; renal cell carcinoma; tumorigenesis

Funding

  1. Korea government (MEST) [0720460, A090281, NRF-2010-0018896, A080181, S2-2008-000-00400-1]
  2. Korea Health Promotion Institute [A090281, A080181, 0720460] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Germline mutations in the von Hippel-Lindau (VHL) tumor suppressor gene cause VHL disease, a rare and autosomal-dominant genetic syndrome. Because VHL protein (pVHL) is the master regulator of hypoxia-inducible factor alpha (HIF alpha), the most prominent feature of VHL disease is the deregulation of HIF alpha proteins. However, the precise mechanism by which the loss of pVHL function contributes to tumorigenesis is not fully understood. Here, we show that pVHL destabilizes the F-box protein Skp2, a chief component of Skp, Cullin, F-box-containing complex that promotes DNA synthesis in the S phase. The beta-domain of pVHL interacts with Skp2, stimulating proteasome-dependent Skp2 degradation, but the destabilization of Skp2 does not depend on the E3 ubiquitin ligase activity of pVHL. Notably, the generation of DNA damage induces Skp2 degradation, which is attenuated by the suppression of endogenous pVHL expression. One possible mechanism of pVHL-dependent Skp2 degradation entails the antagonizing of Akt-mediated Skp2 phosphorylation, which maintains Skp2 stability. Reintroduction of VHL into VHL-null renal cell carcinoma (RCC) cells decreased Skp2 levels and restored DNA damage-dependent Skp2 degradation. These results identify the tumor suppressor function of pVHL in delaying the S-phase progression to inhibit cell proliferation on DNA damage. Clinically, this report explains as to why Skp2 accumulates abnormally in RCC tissues. Oncogene (2011) 30, 3127-3138; doi:10.1038/onc.2011.40; published online 28 February 2011

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available